Human African trypanosomiasis in travellers to Kenya.
- MedicineEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
In this issue, two cases are described of human African trypanosomiasis (HAT) due to Trypanosoma brucei rhodesiense. They occurred recently in European tourists returning from Masai Mara area, Kenya,…
Clinical features, diagnosis, and treatment of human African trypanosomiasis (sleeping sickness)
- MedicineThe Lancet Neurology
Development of novel drugs for human African trypanosomiasis.
- BiologyFuture microbiology
Novel benzoxaboroles, discovered by Anacor, Scynexis and DNDi, have good pharmacokinetic properties in plasma and in the brain and are curative in a murine model of stage two HAT with brain infection.
Future treatment options for human African trypanosomiasis
- MedicineExpert review of anti-infective therapy
It is essential that research continues to identify novel molecules as it will result in the absence of molecules in the pipeline to fall back on should the current clinical trials be unsuccessful, resulting in a resurgence in the number of HAT cases.
The detection and treatment of human African trypanosomiasis.
- MedicineResearch and reports in tropical medicine
The use of noninvasive ambulatory polysomnography is proposed to identify sleep-wake abnormalities characteristic of stage 2 of the disease, between these still controversial thresholds of Rhodesian HAT.
In vitro studies and in vivo evaluation of novel diamidines for 2nd stage sleeping sickness
DB868 is a good candidate drug to cure first stage sleeping sickness by an oral treatment, as demonstrated in mice and monkeys with first stage infections and 28DAP010 inhibited the heat production of trypanosome cultures faster than DB829.
Human African trypanosomiasis: What are the prospects for control?
The prospects for control of HAT comprise a spectrum of developments, from new tools for disease diagnosis and staging, tsetse control, and prevention of transmission, to more effective and non-toxic treatment options, including immune therapies.
Diversity of response to Trypanosoma brucei gambiense infections in the Forecariah mangrove focus (Guinea): perspectives for a better control of sleeping sickness.
- MedicineMicrobes and infection
Delivery of antihuman African trypanosomiasis drugs across the blood-brain and blood-CSF barriers.
- BiologyAdvances in pharmacology
SHOWING 1-10 OF 179 REFERENCES
Biological diagnosis of human African trypanosomiasis
Human African trypanosomiasis or sleeping sickness is an endemic disease in many sub-Saharan countries, and the more chronic “Gambian” form, which evolves fatally over a period of several months or years, predominates in West and Central Africa.
The Burden of Human African Trypanosomiasis
- MedicinePLoS neglected tropical diseases
This work highlights areas where data are lacking to properly quantify the impact of these diseases, mainly relating to quantifying under-reporting and disability associated with infection, and challenges the HAT research community to tackle the neglect in data gathering to enable better evidence-based assessments of burden.
Imported African trypanosomiasis in the United States.
- MedicineAnnals of internal medicine
All cases responded to therapy although one relapsed, and the early diagnosis of sleeping sickness requires that physicians be cognizant of the possibility of imported tropical diseases.
The challenge of Trypanosoma brucei gambiense sleeping sickness diagnosis outside Africa.
- MedicineThe Lancet. Infectious diseases
Human African trypanosomiasis in endemic populations and travellers
- MedicineEuropean Journal of Clinical Microbiology & Infectious Diseases
The symptomatology of travellers is markedly different from the usual textbook descriptions of African HAT patients and a promising new drug combination is currently evaluated in a phase 3 b study and further new drugs are under evaluation.
African Trypanosomiasis Gambiense, Italy
- MedicineEmerging infectious diseases
Two cases diagnosed in the summer of 2004 suggest an increased risk for expatriates working in trypanosomiasis-endemic countries and travel medicine clinics should be increasingly aware of this potentially fatal disease.
Human African Trypanosomiasis in Areas without Surveillance
- MedicineEmerging infectious diseases
The above-listed examples illustrate that many HAT patients are still found in historical foci that have been devoid of active surveillance for years or decades because of their remoteness, insecurity, neglect, or a combination of these factors.
The history of African trypanosomiasis
- MedicineParasites & Vectors
Current history of human African trypanosomiasis has shown that the production of anti-sleeping sickness drugs is not always guaranteed, and therefore, new, better and cheaper drugs are urgently required.
Human African trypanosomiasis–neurological aspects
- MedicineJournal of Neurology
There is a pressing need for a non–toxic oral drug for both early and late stage disease that would obviate many of the problems of staging, and various possible strategies to achieve this goal are currently underway.